Last week, the firm launched AtheroGxOne the second of two cardiovascular next-gen sequencing panels, and hopes to launch its first liquid biopsy test in 2017.
The partners will develop panels to stratify patients with obesity and diabetes into surgical and alternate intervention groups in an upcoming clinical trial.
The New Jersey-based molecular diagnostics firm said it is planning to use the capital to "expand operations aggressively" and accelerate product development efforts.
NEW YORK (GenomeWeb News) – GeneWiz and Beijing ACCB Biotech today said they are collaborating on next-generation sequencing-based tests for the clinical market.
A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.
South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.
